Pharmaceuticals

Neurodegenerative Disease Market Anticipated to Record Steady Gains, Advancing to $88.5 Billion by 2030

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neurodegenerative disease market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Neurodegenerative Disease Market reach by 2030 starting from 2026 levels?

The market for neurodegenerative diseases has shown substantial growth in recent times. This market is projected to expand from $57.23 billion in 2025 to $62.59 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 9.4%. Historically, factors contributing to this growth include a restricted comprehension of disease pathology, a dependence on traditional symptomatic therapies, an expanding aging demographic, the enhancement of healthcare infrastructure dedicated to neurology, and a scarcity of sophisticated diagnostic instruments.

The neurodegenerative disease market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $88.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.0%. Key factors contributing to this growth during the forecast period include progress in gene and cell therapies, increased research and development efforts for innovative neuroprotective medications, the broadening of clinical trial networks, the incorporation of AI for timely diagnosis and patient surveillance, and the growing embrace of personalized medicine strategies. Significant trends observed within the forecast timeframe encompass the increasing occurrence of neurodegenerative conditions, a surge in funding for drug development and clinical studies, the uptake of targeted and individualized treatments, enhanced awareness and early detection initiatives, and the expansion of care solutions delivered both at home and in outpatient settings.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24618&type=smp

Which Drivers Are Influencing Long-Term Growth In The Neurodegenerative Disease Market?

Elevated levels of research and clinical trials are anticipated to drive the expansion of the neurodegenerative disease market in the future. These trials involve scientific investigations carried out on human subjects to assess the safety, effectiveness, and possible adverse reactions of novel therapies, medications, or medical instruments. This surge in research and trials largely stems from a growing need for innovative treatments to meet changing healthcare requirements and enhance results for patients. They are crucial for neurodegenerative disease studies, offering vital information on the safety and efficacy of emerging treatments, thereby fostering therapeutic progress and bettering patient health. As an illustration, a December 2024 report from the UK-based Association of the British Pharmaceutical Industry (ABPI) indicated that the volume of UK industry clinical trials started increased by 3.7% in 2023 relative to 2022. Consequently, the expanding volume of research and clinical trials is projected to fuel the growth of the neurodegenerative disease market.

How Is The Neurodegenerative Disease Market Divided Into Segments?

The neurodegenerative disease market covered in this report is segmented –

1) By Disease Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis

2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types

3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospital, Retail, Online

Subsegments:

1) By Parkinson’s Disease: Idiopathic Parkinson’s Disease, Familial Parkinson’s Disease, Early-Onset Parkinson’s Disease, Parkinsonism

2) By Alzheimer’s Disease: Early-Onset Alzheimer’s Disease, Late-Onset Alzheimer’s Disease, Familial Alzheimer’s Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype

3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)

4) By Huntington’s Disease: Adult-Onset Huntington’s Disease, Juvenile Huntington’s Disease

5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)

What Trends Are Driving The Growth Trajectory Of The Neurodegenerative Disease Market?

Major companies within the neurodegenerative disease market are concentrating on developing innovative products, such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, to enhance treatment precision, improve disease-modifying effects, and elevate patient quality of life. These next-generation adaptive deep brain stimulation (aDBS) systems are sophisticated neurostimulation devices engineered to deliver real-time, personalized treatment for Parkinson’s disease by dynamically adjusting stimulation parameters based on neural feedback, thereby optimizing therapeutic effects and minimizing side effects for better patient outcomes. For instance, in February 2025, Medtronic, a US-based medical technology company, secured approval from the U.S. Food and Drug Administration (USFDA) for the world’s first adaptive deep brain stimulation (aDBS) system designed for Parkinson’s disease. This approval specifically concerns the premarket approval (PMA) application for the Percept RC neurostimulator, which features BrainSense technology that automatically modifies therapy in response to a patient’s brain signals. The system has been clinically validated to offer symptom relief for patients with advanced Parkinson’s disease and signifies a major leap forward in personalized neuromodulation therapies.

Which Major Firms Are Strengthening Their Position In The Neurodegenerative Disease Market?

Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disease-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Neurodegenerative Disease Market?

North America was the largest region in the neurodegenerative disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neurodegenerative Disease Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24618&type=smp

Browse Through More Reports Similar to the Global Neurodegenerative Disease Market 2026, By The Business Research Company

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Degenerative Disc Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/degenerative-disc-disease-treatment-global-market-report

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795